A pilot study using remote monitoring technology developed by Locus Health in cancer patients undergoing chemotherapy treatment.

Modern-day wearable devices, such as Apple Watches or Fitbits, are widely available, non-invasive, and can provide continuous vital sign monitoring for the early detection of potential health complications. Early detection of things such as fever or increased heart rate can alert patients to seek medical attention sooner and therefore have the potential to improve patient outcomes and decrease healthcare costs.

To further investigate the feasibility of using remote patient monitoring ( RPM)to prospectively monitor patients undergoing outpatient chemotherapy for chemotherapy related toxicities, defined as follows: (1) patients answer queries through the Locus Health iPhone app at least 70% of the time; (2) patients report that the Locus Health iPhone app and the Apple Watch were 'easy to use,' defined as an average score of 7 or higher on the first two questions of the post-intervention questionnaire, and (3) fewer than 10% of patients withdraw from the study.

Inclusion Criteria:

• Planned to be treated with a new cytotoxic chemotherapy or chemoimmunotherapy regimen for a solid tumor or malignant hematology condition for at least 4 months
• ECOG performance status of 0-2
• Age of 18 or older patient with any solid tumor or hematologic malignancy
• English or Spanish speaker
• Own an Apple iPhone
• Capacity and willingness to provide informed consent

Exclusion Criteria:

• Patients undergoing concurrent radiation since they will be seen on a daily basis by clinic care teams and are not likely to benefit from active remote patient monitoring
• Patients unwilling or unable to comply with the protocol, including wearing the Apple Watch (including recharging daily) and answering queries on the Locus Health iPhone application per the protocol and study group cadence
• Any condition for which in the Investigator's opinion would limit compliance with study requirements

Patients with a wide range of solid tumor and malignant hematology malignancies will be enrolled

• Age, gender, race/ethnicity
• Active Problem List
• Past Medical History
• Past Surgical History
• Social History
• Vital Measurements from each clinic visit
• Lab Results
• Medication Orders

If the patient is seen in the Emergency Room or hospitalized, the following data will be extracted:

• ER/Hospital Based Problem List
• ER/ Hospital reason for presentation/Admission
• Hospital Admission Diagnoses

The Apple/Locus Health RPM intervention will end and the patient will come off study when the chemotherapy regimen is stopped for any reason.

All patient records and end-of study questionnaires will be de-identified using a letter and number assigned to their case at the time of enrollment on study. No record used for the data analysis will contain information which could identify the patient. Only the delegated research team will have access to the 'key' which connects patient identifiable information with this assigned number For computer records, the key will be protected by a double-password protection system. Any paper records will be contained in a locked cabinet within a locked office to ensure patients' privacy is protected.